For Our Patients
Clinical Trials and Research
All Upcoming
Studies
Clinical trials are designed to test the safety and efficacy of new approaches to preventing, detecting, and treating disease. Research and clinical trials also continuously look for new ways to use existing treatments, new drugs, surgical procedures and devices.
Florida Retina Institute clinical trial participants may enroll to possibly receive the newest treatment for their vitreoretinal conditions, as well as to have additional care and attention from clinical trial staff and with the results and outcome of their trial, help researchers find better treatments for future patients.
Detailed information about all Upcoming Studies
For Central Florida Patients
EyeBio
Study/Protocol Number: EYE-RES-102(BRUNELLO)
Title: A Phase 2/3 Randomized, Double-masked, Dose finding, Safety and Efficacy study comparing 2 doses of EYE103 to anti-VEGF in participants with diabetic macular edema (DME)
Eyepoint
Study/Protocol Number: EYP-1901-301 (LUGANO)
Title: A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept, in Subjects with Wet AMD
Regeneron RVO
Title: REGENERON, VGFTe-HD-RVO-2335, A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 mg Aflibercept in Participants with Macular Edema following Retinal Vein Occlusion, Parexel Number 283871
Regeneron Pharmaceutics, INC, R3918-AMD-2326 and R3918-AMD-2327 for GA
Regeneron Pharmaceutics, INC, R3918-AMD-2326 and R3918-AMD-2327, A Randomized, Placebo-Controlled Study of Subcutaneous Pozelimab + Cemdisiran Combination Therapy or Cemdisiran Monotherapy for the Treatment of Geographic Atrophy, 284291
Stealth Dry AMD
Title: Regeneron Pharmaceutics, INC, R3918-AMD-2326 and R3918-AMD-2327, A Randomized, Placebo-Controlled Study of Subcutaneous Pozelimab + Cemdisiran Combination Therapy or Cemdisiran Monotherapy for the Treatment of Geographic Atrophy, 284291
For North Florida Patients
Upcoming Soon!
R3918-AMD-2326/2327 Regeneron Pharmaceutics,INC - Dry AMD (GA)
A Randomized, Placebo-Controlled Study of Subcutaneous Pozelimab +
Cemdisiran Combination Therapy or Cemdisiran Monotherapy for the
Treatment of Georgraphic Atrophy, 284291
If you want to see a list of clinical trials, please click here and go to Clinicaltrials.gov, a resource provided by the U.S. National Library of Medicine. ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.
